Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study

NCT07549906 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Colon Cancer (Stage II &Amp; III)
Immunotherapy
Beta Blocker
Neoadjuvant Chemoimmunotherapy

Interventions

DRUG: Iparomlimab/Tuvonralimab
DRUG: Capecitabine
DRUG: Oxaliplatin
DRUG: Propranolol

Sponsor

Sun Yat-sen University